FIG 2.

TDF does not trigger an inflammatory cytokine or chemokine response in the female genital tract. Mice pretreated with medroxyprogesterone received 30 μl of gel intravaginally twice daily for three or seven consecutive days. (A) Protein levels were measured in vaginal washes by a Luminex assay. Washes were grouped into pools of 2 mice, and five to eight pools per treatment arm were evaluated. The data are presented as means plus standard errors of the means. (B) RNA was extracted from genital tract tissue, reverse transcribed, and analyzed by qPCR for the indicated cytokine or chemokine gene. Data are presented as means plus standard errors of the means from 6 to 8 mice per group. Asterisks indicate significance compared to untreated mice using one-way ANOVA, with Tukey's test for multiple comparisons (P < 0.05). There were no statistically significant differences between HEC- and TDF-treated groups.